TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3340
AB  - Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach
VL  - 38
IS  - 3
SP  - 323
EP  - 331
DO  - 10.2478/jomb-2018-0030
ER  - 

@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2019",
abstract = "Background: Due to wide intra- and inter-individual pharmacokinetic variability and narrow therapeutic index of sirolimus, the therapeutic drug monitoring (TDM) of sirolimus with detailed biochemical and clinical monitoring is necessary for dose individualization in kidney transplant patients. The purpose of the study was to explore and identify factors that contribute to pharmacokinetic variability by developing and validating a population model using routine TDM data and routinely monitored biochemical and clinical parameters. Methods: The data obtained by routine monitoring of 38 patients over a period of one year from the sirolimus treatment initiation, were collected from patients' records. Population analysis was performed using the software NONMEM (R). The validity of the model was tested by the internal and external validation techniques. Results: The pharmacokinetic variability was partially explained with patient's age and liver function. CL/F was found to decrease with age. According to the developed model, sirolimus CL/F decreases by, in average, 37% in patients with aspartate aminotransferase (AST) greater than 37 IU/L. The internal and external validation confirmed the satisfactory prediction of the developed model. Conclusions: The population modeling of routinely monitored data allowed quantification of the age and liver function influence on sirolimus CL/F. According to the final model, patients with compromised liver function expressed via AST values require careful monitoring and dosing adjustments. Proven good predictive performance makes this model a useful tool in everyday clinical practice.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach",
volume = "38",
number = "3",
pages = "323-331",
doi = "10.2478/jomb-2018-0030"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2019). Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 323-331.
https://doi.org/10.2478/jomb-2018-0030

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach. in Journal of Medical Biochemistry. 2019;38(3):323-331.
doi:10.2478/jomb-2018-0030 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients-population pharmacokinetic approach" in Journal of Medical Biochemistry, 38, no. 3 (2019):323-331,
https://doi.org/10.2478/jomb-2018-0030 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Golubović, Bojana
AU  - Jovanović, Marija
AU  - de Gier, Johan J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2985
AB  - Objective: To evaluate elderly polypharmacy patients' needs and concerns regarding medication through the Structured Patient-Pharmacist Consultation (SPPC). Methods: Older patients on chronic treatment with > 5 medications were asked to fill in the SPPC form at home. A consultation with the community pharmacist, structured according to patient's answers, followed within 2-4 weeks. Logistic regression associated patients' individual treatment with care issues and consultation outcomes. Results: Out of 440 patients, 39.5% experienced problems, and 46.1% had concerns about medication use. 122 patients reported reasons for discontinuing treatment. The main outcome of the consultation was a better understanding of medication use (75.5%). Side effects and/or non-adherence were identified in 50% of patients, and 26.6% were referred to the doctor. Atrial fibrillation, COPD, anticoagulants, benzodiazepines, and beta agonists/corticosteroids were associated with problems during medication use. Patients with diabetes improved their understanding of medication use significantly. Conclusion: Patients on benzodiazepines, anticoagulants, and beta agonists/corticosteroids, with atrial fibrillation and/or COPD, may have a higher potential for non-adherence. Counseling patients based on the SPPC model may be particularly useful for patients with diabetes.
PB  - Elsevier Ireland Ltd, Clare
T2  - Patient Education and Counseling
T1  - Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model
VL  - 100
IS  - 9
SP  - 1714
EP  - 1719
DO  - 10.1016/j.pec.2017.05.001
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Miljković, Branislava and Vučićević, Katarina and Ćulafić, Milica and Kovačević, Milena and Golubović, Bojana and Jovanović, Marija and de Gier, Johan J.",
year = "2017",
abstract = "Objective: To evaluate elderly polypharmacy patients' needs and concerns regarding medication through the Structured Patient-Pharmacist Consultation (SPPC). Methods: Older patients on chronic treatment with > 5 medications were asked to fill in the SPPC form at home. A consultation with the community pharmacist, structured according to patient's answers, followed within 2-4 weeks. Logistic regression associated patients' individual treatment with care issues and consultation outcomes. Results: Out of 440 patients, 39.5% experienced problems, and 46.1% had concerns about medication use. 122 patients reported reasons for discontinuing treatment. The main outcome of the consultation was a better understanding of medication use (75.5%). Side effects and/or non-adherence were identified in 50% of patients, and 26.6% were referred to the doctor. Atrial fibrillation, COPD, anticoagulants, benzodiazepines, and beta agonists/corticosteroids were associated with problems during medication use. Patients with diabetes improved their understanding of medication use significantly. Conclusion: Patients on benzodiazepines, anticoagulants, and beta agonists/corticosteroids, with atrial fibrillation and/or COPD, may have a higher potential for non-adherence. Counseling patients based on the SPPC model may be particularly useful for patients with diabetes.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Patient Education and Counseling",
title = "Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model",
volume = "100",
number = "9",
pages = "1714-1719",
doi = "10.1016/j.pec.2017.05.001"
}

Vezmar-Kovačević, S., Miljković, B., Vučićević, K., Ćulafić, M., Kovačević, M., Golubović, B., Jovanović, M.,& de Gier, J. J.. (2017). Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model. in Patient Education and Counseling
Elsevier Ireland Ltd, Clare., 100(9), 1714-1719.
https://doi.org/10.1016/j.pec.2017.05.001

Vezmar-Kovačević S, Miljković B, Vučićević K, Ćulafić M, Kovačević M, Golubović B, Jovanović M, de Gier JJ. Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model. in Patient Education and Counseling. 2017;100(9):1714-1719.
doi:10.1016/j.pec.2017.05.001 .

Vezmar-Kovačević, Sandra, Miljković, Branislava, Vučićević, Katarina, Ćulafić, Milica, Kovačević, Milena, Golubović, Bojana, Jovanović, Marija, de Gier, Johan J., "Elderly polypharmacy patients' needs and concerns regarding medication assessed using the structured patient-pharmacist consultation model" in Patient Education and Counseling, 100, no. 9 (2017):1714-1719,
https://doi.org/10.1016/j.pec.2017.05.001 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Golubović, Bojana
AU  - Jovanović, Marija
AU  - Vezmar-Kovačević, Sandra
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - de Gier, Johan J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2892
AB  - Background: During the initiation of treatment of a chronic disease, patients may have varying interests, expectations, concerns, and reasons to stop treatment, influencing compliance with prescribed treatment. Thus, healthcare professionals are expected to integrate these needs into medicines management. Objectives: To determine what information is important to patients; assess predictors of patients' interests, expectations, concerns, reasons to stop therapy; evaluate drug-related problems following initiation of therapy and summarize how pharmacists resolve them during patient-pharmacist counselling. Methods: In 2014, a four-month study was performed in Serbian community pharmacies, as part of the Pharmaceutical Care Quality Indicators Project led by the European Directorate for the Quality of Medicines & Healthcare. Seventy community pharmacists were asked to participate in the study. Pharmacists recruited adult patients who consented to participate in the study and who initiated treatment, lasting at least six months. Patients completed an open-ended questions form. After two-to-four weeks, a patient-pharmacist consultation was performed. Results: Forty-four community pharmacists (response rate 62.9%) sent back the completed forms from 391 patients (response rate 67.1%). The total number of dispensed drugs was 403. In terms of drug safety, 29.4% of patients sought information, 32.5% expressed concerns, and 28.1% of patients cited it as a reason to discontinue treatment. During the first weeks of therapy, 18% of patients experienced practical problems, while 27.3% reported adverse drug reactions. Conclusion: Safety issues are a major focus of patients' prescribed new medicines for long-term treatment.
PB  - Taylor & Francis Ltd, Abingdon
T2  - European Journal of General Practice
T1  - Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia
VL  - 24
IS  - 1
SP  - 19
EP  - 25
DO  - 10.1080/13814788.2017.1388778
ER  - 

@article{
author = "Vučićević, Katarina and Miljković, Branislava and Golubović, Bojana and Jovanović, Marija and Vezmar-Kovačević, Sandra and Ćulafić, Milica and Kovačević, Milena and de Gier, Johan J.",
year = "2017",
abstract = "Background: During the initiation of treatment of a chronic disease, patients may have varying interests, expectations, concerns, and reasons to stop treatment, influencing compliance with prescribed treatment. Thus, healthcare professionals are expected to integrate these needs into medicines management. Objectives: To determine what information is important to patients; assess predictors of patients' interests, expectations, concerns, reasons to stop therapy; evaluate drug-related problems following initiation of therapy and summarize how pharmacists resolve them during patient-pharmacist counselling. Methods: In 2014, a four-month study was performed in Serbian community pharmacies, as part of the Pharmaceutical Care Quality Indicators Project led by the European Directorate for the Quality of Medicines & Healthcare. Seventy community pharmacists were asked to participate in the study. Pharmacists recruited adult patients who consented to participate in the study and who initiated treatment, lasting at least six months. Patients completed an open-ended questions form. After two-to-four weeks, a patient-pharmacist consultation was performed. Results: Forty-four community pharmacists (response rate 62.9%) sent back the completed forms from 391 patients (response rate 67.1%). The total number of dispensed drugs was 403. In terms of drug safety, 29.4% of patients sought information, 32.5% expressed concerns, and 28.1% of patients cited it as a reason to discontinue treatment. During the first weeks of therapy, 18% of patients experienced practical problems, while 27.3% reported adverse drug reactions. Conclusion: Safety issues are a major focus of patients' prescribed new medicines for long-term treatment.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "European Journal of General Practice",
title = "Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia",
volume = "24",
number = "1",
pages = "19-25",
doi = "10.1080/13814788.2017.1388778"
}

Vučićević, K., Miljković, B., Golubović, B., Jovanović, M., Vezmar-Kovačević, S., Ćulafić, M., Kovačević, M.,& de Gier, J. J.. (2017). Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia. in European Journal of General Practice
Taylor & Francis Ltd, Abingdon., 24(1), 19-25.
https://doi.org/10.1080/13814788.2017.1388778

Vučićević K, Miljković B, Golubović B, Jovanović M, Vezmar-Kovačević S, Ćulafić M, Kovačević M, de Gier JJ. Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia. in European Journal of General Practice. 2017;24(1):19-25.
doi:10.1080/13814788.2017.1388778 .

Vučićević, Katarina, Miljković, Branislava, Golubović, Bojana, Jovanović, Marija, Vezmar-Kovačević, Sandra, Ćulafić, Milica, Kovačević, Milena, de Gier, Johan J., "Expectations, concerns, and needs of patients who start drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia" in European Journal of General Practice, 24, no. 1 (2017):19-25,
https://doi.org/10.1080/13814788.2017.1388778 . .

TY  - JOUR
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Golubović, Bojana
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - de Gier, Johan J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2811
AB  - Aims and Objectives Targeting older patients with predictive factors for drug-related problems (DRPs) could make clinical medication reviews more cost-effective. The aim of this study was to identify the number, type, and potential predictive factors for DRPs in older polypharmacy patients. Methods Community pharmacists performed clinical medication reviews and documented DRPs, types of interventions, and their implementation in older patients. Results Three hundred eighty-eight medication reviews were analyzed, 964 DRPs (average 2.51.9), and 1022 interventions (average 2.6 +/- 2.0) were identified. The overall implementation rate of interventions was 70.1%, the highest was observed in interventions aiming to resolve the lack of therapy monitoring (86.8%). Patients with 12 medications had an increased risk of 5 DRPs (P  lt  .001). Asthma was associated with lack of adherence (P = .002), lack of aspirin, statins, and proton pump inhibitors use with additional therapy needed (P = .002-.004). Predictive factors for drug interactions were antihypertensive medications and/or medications with narrow therapeutic index (P  lt  .05). Lack of efficacy was associated with diabetes (P = .006). Nonsteroidal anti-inflammatory drugs were risk factors for inappropriate drug selection (P = .002). Lack of monitoring was associated with hypertension (P = .013), whereas benzodiazepines (P  lt  .001) and aspirin (P = .021) were overused. Conclusion Patients with asthma, hypertension, and diabetes and lack of statin, antithrombotic agent, and/or proton pump inhibitor use were associated with higher risks for DRPs.
PB  - Wiley, Hoboken
T2  - Journal of Evaluation in Clinical Practice
T1  - Evaluation of drug-related problems in older polypharmacy primary care patients
VL  - 23
IS  - 4
SP  - 860
EP  - 865
DO  - 10.1111/jep.12737
ER  - 

@article{
author = "Vezmar-Kovačević, Sandra and Miljković, Branislava and Ćulafić, Milica and Kovačević, Milena and Golubović, Bojana and Jovanović, Marija and Vučićević, Katarina and de Gier, Johan J.",
year = "2017",
abstract = "Aims and Objectives Targeting older patients with predictive factors for drug-related problems (DRPs) could make clinical medication reviews more cost-effective. The aim of this study was to identify the number, type, and potential predictive factors for DRPs in older polypharmacy patients. Methods Community pharmacists performed clinical medication reviews and documented DRPs, types of interventions, and their implementation in older patients. Results Three hundred eighty-eight medication reviews were analyzed, 964 DRPs (average 2.51.9), and 1022 interventions (average 2.6 +/- 2.0) were identified. The overall implementation rate of interventions was 70.1%, the highest was observed in interventions aiming to resolve the lack of therapy monitoring (86.8%). Patients with 12 medications had an increased risk of 5 DRPs (P  lt  .001). Asthma was associated with lack of adherence (P = .002), lack of aspirin, statins, and proton pump inhibitors use with additional therapy needed (P = .002-.004). Predictive factors for drug interactions were antihypertensive medications and/or medications with narrow therapeutic index (P  lt  .05). Lack of efficacy was associated with diabetes (P = .006). Nonsteroidal anti-inflammatory drugs were risk factors for inappropriate drug selection (P = .002). Lack of monitoring was associated with hypertension (P = .013), whereas benzodiazepines (P  lt  .001) and aspirin (P = .021) were overused. Conclusion Patients with asthma, hypertension, and diabetes and lack of statin, antithrombotic agent, and/or proton pump inhibitor use were associated with higher risks for DRPs.",
publisher = "Wiley, Hoboken",
journal = "Journal of Evaluation in Clinical Practice",
title = "Evaluation of drug-related problems in older polypharmacy primary care patients",
volume = "23",
number = "4",
pages = "860-865",
doi = "10.1111/jep.12737"
}

Vezmar-Kovačević, S., Miljković, B., Ćulafić, M., Kovačević, M., Golubović, B., Jovanović, M., Vučićević, K.,& de Gier, J. J.. (2017). Evaluation of drug-related problems in older polypharmacy primary care patients. in Journal of Evaluation in Clinical Practice
Wiley, Hoboken., 23(4), 860-865.
https://doi.org/10.1111/jep.12737

Vezmar-Kovačević S, Miljković B, Ćulafić M, Kovačević M, Golubović B, Jovanović M, Vučićević K, de Gier JJ. Evaluation of drug-related problems in older polypharmacy primary care patients. in Journal of Evaluation in Clinical Practice. 2017;23(4):860-865.
doi:10.1111/jep.12737 .

Vezmar-Kovačević, Sandra, Miljković, Branislava, Ćulafić, Milica, Kovačević, Milena, Golubović, Bojana, Jovanović, Marija, Vučićević, Katarina, de Gier, Johan J., "Evaluation of drug-related problems in older polypharmacy primary care patients" in Journal of Evaluation in Clinical Practice, 23, no. 4 (2017):860-865,
https://doi.org/10.1111/jep.12737 . .

TY  - CONF
AU  - Golubović, Bojana
AU  - Drndarević, Aneta
AU  - Draganov, Ivana
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Vučićević, Katarina
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2720
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Potential drug-drug interactions in kidney transplant patients.
VL  - 36
IS  - 7
SP  - e96
EP  - e96
DO  - 10.1002/phar.1782
ER  - 

@conference{
author = "Golubović, Bojana and Drndarević, Aneta and Draganov, Ivana and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Vučićević, Katarina and Prostran, Milica and Miljković, Branislava",
year = "2016",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Potential drug-drug interactions in kidney transplant patients.",
volume = "36",
number = "7",
pages = "e96-e96",
doi = "10.1002/phar.1782"
}

Golubović, B., Drndarević, A., Draganov, I., Radivojević, D., Vezmar-Kovačević, S., Vučićević, K., Prostran, M.,& Miljković, B.. (2016). Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 36(7), e96-e96.
https://doi.org/10.1002/phar.1782

Golubović B, Drndarević A, Draganov I, Radivojević D, Vezmar-Kovačević S, Vučićević K, Prostran M, Miljković B. Potential drug-drug interactions in kidney transplant patients.. in Pharmacotherapy. 2016;36(7):e96-e96.
doi:10.1002/phar.1782 .

Golubović, Bojana, Drndarević, Aneta, Draganov, Ivana, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Vučićević, Katarina, Prostran, Milica, Miljković, Branislava, "Potential drug-drug interactions in kidney transplant patients." in Pharmacotherapy, 36, no. 7 (2016):e96-e96,
https://doi.org/10.1002/phar.1782 . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Prostran, Milica
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Grabnar, Iztok
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2678
AB  - Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Medicinal Chemistry
T1  - Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients
VL  - 23
IS  - 19
SP  - 1998
EP  - 2011
DO  - 10.2174/0929867323666151221150214
ER  - 

@article{
author = "Golubović, Bojana and Prostran, Milica and Miljković, Branislava and Vučićević, Katarina and Radivojević, Dragana and Grabnar, Iztok",
year = "2016",
abstract = "Immunosuppressive therapy is the cornerstone of successful kidney transplantation. Frequently used immunosuppressives are cyclosporine, tacrolimus, sirolimus and mycophenolic acid. These drugs have narrow therapeutic index and show high pharmacokinetic variability. In order to maintain the balance between efficacy and safety, dosing is based on measured drug concentrations. Proper identification, quantification and understanding the sources of variability in measured concentrations facilitate routine dose adjustment in clinical practice. Classical pharmacokinetic studies have limited use in transplant patients attributable to design with intense sampling in a small, relatively homogenous population, and identification of only single variability factor per study. Population approach is a powerful tool for analysing sparse data, identifying factors that influence drug pharmacokinetics and estimating variability. In this report we reviewed available population pharmacokinetic models for cyclosporine, tacrolimus, sirolimus and mycophenolic acid in adult kidney transplant patients. The major focus was to describe various demographic factors, biochemical parameters, genetic polymorphisms of metabolic enzymes and transporters and drug-drug interactions, which have been identified as an important concern of pharmacokinetic variability in kidney transplant patients.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Medicinal Chemistry",
title = "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients",
volume = "23",
number = "19",
pages = "1998-2011",
doi = "10.2174/0929867323666151221150214"
}

Golubović, B., Prostran, M., Miljković, B., Vučićević, K., Radivojević, D.,& Grabnar, I.. (2016). Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 23(19), 1998-2011.
https://doi.org/10.2174/0929867323666151221150214

Golubović B, Prostran M, Miljković B, Vučićević K, Radivojević D, Grabnar I. Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients. in Current Medicinal Chemistry. 2016;23(19):1998-2011.
doi:10.2174/0929867323666151221150214 .

Golubović, Bojana, Prostran, Milica, Miljković, Branislava, Vučićević, Katarina, Radivojević, Dragana, Grabnar, Iztok, "Population Pharmacokinetic Approach of Immunosuppressive Therapy in Kidney Transplant Patients" in Current Medicinal Chemistry, 23, no. 19 (2016):1998-2011,
https://doi.org/10.2174/0929867323666151221150214 . .

TY  - JOUR
AU  - Vučićević, Katarina
AU  - Jovanović, Marija
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Martinović, Žarko J.
AU  - Prostran, Milica
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2408
AB  - The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients
VL  - 71
IS  - 2
SP  - 183
EP  - 190
DO  - 10.1007/s00228-014-1778-7
ER  - 

@article{
author = "Vučićević, Katarina and Jovanović, Marija and Golubović, Bojana and Vezmar-Kovačević, Sandra and Miljković, Branislava and Martinović, Žarko J. and Prostran, Milica",
year = "2015",
abstract = "The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients. In total 205 PB concentrations were obtained during routine clinical monitoring of 136 adult epilepsy patients. PB steady state concentrations were measured by homogeneous enzyme immunoassay. Nonlinear mixed effects modelling (NONMEM) was applied for data analyses and evaluation of the final model. According to the final population model, significant determinant of apparent PB clearance (CL/F) was daily dose of concomitantly given valproic acid (VPA). Typical value of PB CL/F for final model was estimated at 0.314 l/h. Based on the final model, co-therapy with usual VPA dose of 1000 mg/day, resulted in PB CL/F average decrease of about 25 %, while 2000 mg/day leads to an average 50 % decrease in PB CL/F. Developed population PB model may be used in estimating individual CL/F for adult epileptic patients and could be applied for individualizing dosing regimen taking into account dose-dependent effect of concomitantly given VPA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients",
volume = "71",
number = "2",
pages = "183-190",
doi = "10.1007/s00228-014-1778-7"
}

Vučićević, K., Jovanović, M., Golubović, B., Vezmar-Kovačević, S., Miljković, B., Martinović, Ž. J.,& Prostran, M.. (2015). Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 71(2), 183-190.
https://doi.org/10.1007/s00228-014-1778-7

Vučićević K, Jovanović M, Golubović B, Vezmar-Kovačević S, Miljković B, Martinović ŽJ, Prostran M. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. in European Journal of Clinical Pharmacology. 2015;71(2):183-190.
doi:10.1007/s00228-014-1778-7 .

Vučićević, Katarina, Jovanović, Marija, Golubović, Bojana, Vezmar-Kovačević, Sandra, Miljković, Branislava, Martinović, Žarko J., Prostran, Milica, "Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients" in European Journal of Clinical Pharmacology, 71, no. 2 (2015):183-190,
https://doi.org/10.1007/s00228-014-1778-7 . .

TY  - CONF
AU  - Jovanović, Marija
AU  - Vučićević, Katarina
AU  - Golubović, Bojana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Martinović, Žarko J.
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2117
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis
VL  - 24
IS  - Supplement 2
SP  - S645
EP  - S645
DO  - 10.1016/S0924-977X(14)71037-5
ER  - 

@conference{
author = "Jovanović, Marija and Vučićević, Katarina and Golubović, Bojana and Vezmar-Kovačević, Sandra and Prostran, Milica and Martinović, Žarko J. and Miljković, Branislava",
year = "2014",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis",
volume = "24",
number = "Supplement 2",
pages = "S645-S645",
doi = "10.1016/S0924-977X(14)71037-5"
}

Jovanović, M., Vučićević, K., Golubović, B., Vezmar-Kovačević, S., Prostran, M., Martinović, Ž. J.,& Miljković, B.. (2014). No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 24(Supplement 2), S645-S645.
https://doi.org/10.1016/S0924-977X(14)71037-5

Jovanović M, Vučićević K, Golubović B, Vezmar-Kovačević S, Prostran M, Martinović ŽJ, Miljković B. No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis. in European Neuropsychopharmacology. 2014;24(Supplement 2):S645-S645.
doi:10.1016/S0924-977X(14)71037-5 .

Jovanović, Marija, Vučićević, Katarina, Golubović, Bojana, Vezmar-Kovačević, Sandra, Prostran, Milica, Martinović, Žarko J., Miljković, Branislava, "No effect of carbamazepine daily dose on phenobarbital elimination in adult epileptic patients - population pharmacokinetic analysis" in European Neuropsychopharmacology, 24, no. Supplement 2 (2014):S645-S645,
https://doi.org/10.1016/S0924-977X(14)71037-5 . .

TY  - CONF
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2199
PB  - Wiley-Blackwell, Hoboken
C3  - Pharmacotherapy
T1  - Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients
VL  - 34
IS  - 6
SP  - e114
EP  - e114
DO  - 10.1002/phar.1449
ER  - 

@conference{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Pharmacotherapy",
title = "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients",
volume = "34",
number = "6",
pages = "e114-e114",
doi = "10.1002/phar.1449"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy
Wiley-Blackwell, Hoboken., 34(6), e114-e114.
https://doi.org/10.1002/phar.1449

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients. in Pharmacotherapy. 2014;34(6):e114-e114.
doi:10.1002/phar.1449 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Prediction of tacrolimus dose based on estimated clearance using population pharmacokinetic approach in adult kidney transplant patients" in Pharmacotherapy, 34, no. 6 (2014):e114-e114,
https://doi.org/10.1002/phar.1449 . .

TY  - JOUR
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Radivojević, Dragana
AU  - Vezmar-Kovačević, Sandra
AU  - Prostran, Milica
AU  - Miljković, Branislava
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2174
AB  - Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.
PB  - Elsevier Science BV, Amsterdam
T2  - European Journal of Pharmaceutical Sciences
T1  - Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach
VL  - 52
SP  - 34
EP  - 40
DO  - 10.1016/j.ejps.2013.10.008
ER  - 

@article{
author = "Golubović, Bojana and Vučićević, Katarina and Radivojević, Dragana and Vezmar-Kovačević, Sandra and Prostran, Milica and Miljković, Branislava",
year = "2014",
abstract = "Data from routine therapeutic drug monitoring of 105 adult kidney transplant recipients were used for population pharmacokinetic analysis which was performed using a non-linear mixed-effects modeling. The effect of demographic and clinical factors on tacrolimus clearance was evaluated. Following the initiation of treatment with tacrolimus, the results of our study indicate a decrease of the drug clearance on day 15, 1 and 6 months after transplantation for 4.4%, 6.3% and 10.92%, respectively. Our model suggests a negative correlation between tacrolimus clearance and haematocrit. According to final model, clearance decreases with increasing of aspartate aminotransferase. Our results demonstrated that CL/F increases with patients' weight. This study reveals incensement for 10.4% in tacrolimus clearance with alteration of patients' minimal measured total protein levels to upper normal range. The findings of this study explore various factors of tacrolimus pharmacokinetic variability and point out a relationship between tacrolimus clearance and total plasma protein. Developed model demonstrates the feasibility of estimation of individual tacrolimus clearance and may allow rational individualization of tacrolimus dosing in kidney transplant patients.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Journal of Pharmaceutical Sciences",
title = "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach",
volume = "52",
pages = "34-40",
doi = "10.1016/j.ejps.2013.10.008"
}

Golubović, B., Vučićević, K., Radivojević, D., Vezmar-Kovačević, S., Prostran, M.,& Miljković, B.. (2014). Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences
Elsevier Science BV, Amsterdam., 52, 34-40.
https://doi.org/10.1016/j.ejps.2013.10.008

Golubović B, Vučićević K, Radivojević D, Vezmar-Kovačević S, Prostran M, Miljković B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach. in European Journal of Pharmaceutical Sciences. 2014;52:34-40.
doi:10.1016/j.ejps.2013.10.008 .

Golubović, Bojana, Vučićević, Katarina, Radivojević, Dragana, Vezmar-Kovačević, Sandra, Prostran, Milica, Miljković, Branislava, "Total plasma protein effect on tacrolimus elimination in kidney transplant patients - Population pharmacokinetic approach" in European Journal of Pharmaceutical Sciences, 52 (2014):34-40,
https://doi.org/10.1016/j.ejps.2013.10.008 . .

TY  - JOUR
AU  - Antonić, Roland
AU  - Jovanović, Marija
AU  - Golubović, Bojana
AU  - Vučićević, Katarina
AU  - Ćulafić, Milica
AU  - Miljković, Branislava
AU  - Vezmar-Kovačević, Sandra
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2048
AB  - Introduction: Insufficient patient knowledge about asthma treatment and inappropriate inhalation techniques contribute to treatment failure. The aim of this study was to investigate the impact of a pharmaceutical care service for asthma patients on improving knowledge about drug purpose and adverse reactions as well as appropriate inhalation technique. Material and methods: Asthma patients with no previous pharmaceutical care (PC) counseling participated in the study, conducted in Pharmacy 'Šabac' during january-april 2010. Data were collected about purpose of drugs, adverse reactions and inhalation technique. During january-april 2013 the investigation was repeated with patients who were offered PC priorly which comprised verbal and written education about purpose of drugs, adverse reactions and inhalation technique. Results: The first group consisted of 128 and the second of 65 patients, with the same average age (56 years). Patients who were offered PC had better knowledge of drug purpose in asthma treatment (91.4-94.0% vs 62.6-75.0%, p lt 0.01) and increased number of adverse reactions (16.0-17.2% vs 3.7-7.5%). Following PC, inhalation technique improved significantly (70.8% vs 38.3% of patients, p lt 0.001) and the average number of mistakes during inhalation decreased (1.33 vs 0.43, p lt 0.001). Conclusion: Asthma patients have insufficient knowledge about their treatment and often use inhalers inappropriately. Pharmacists, by providing PC can contribute significantly to efficient and safe asthma treatment.
AB  - Uvod: Nedovoljno znanje pacijenata obolelih od astme o savremenoj terapiji i pravilnom načinu njene primene znatno može doprineti neuspehu terapije. Cilj ovog istraživanja bio je ispitivanje doprinosa farmaceutske zdravstvene zaštite (FZZ) edukaciji pacijenata sa astmom, s posebnim osvrtom na pravilnu primenu inhalacione terapije. Materijal i metode: U ispitivanju, sprovedenom u Apoteci 'Šabac' u periodu od januara do aprila 2010. godine, učestvovali su pacijenti sa astmom, kojima prethodno nije pružena FZZ. Prikupljeni su podaci o pacijentima, terapiji koju koriste, neželjenim reakcijama i načinu primene inhalacionih preparata. U periodu od januara do aprila 2013. godine istraživanje je ponovljeno sa pacijentima kojima je prethodno pružena FZZ, koja je obuhvatala pisanu i usmenu edukaciju o nameni lekova, neželjenim reakcijama i pravilnoj tehnici inhalacije. Rezultati: U prvoj grupi je bilo 128, u drugoj 65 pacijenata iste prosečne starosti (56 godina). Pacijenti kojima je pružena FZZ pokazali su bolje znanje o primeni lekova u terapiji astme (91,4-94,0% naspram 62,6-75,0%, p lt 0,01) i povećan je broj neželjenih reakcija (16,0­17,2% naspram 3,7-7,5%). Nakon pružene FZZ, značajno je poboljšana pravilna primena inhalacionih preparata (70,8% naspram 38,3% p lt 0,001) i smanjen je prosečan broj grešaka prilikom inhalacije (1,33 prema 0,43, p lt 0,001). Zaključak: Pacijenti sa astmom nemaju potrebno znanje o inhalacionoj terapiji i često greše u tehnici inhalacije. Farmaceuti, pružanjem usluge FZZ, mogu dati značajan doprinos efikasnoj i bezbednoj terapiji pacijenata sa astmom.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Investigation of the impact of pharmaceutical care on improvement of treatment knowledge and inhalation technique in asthma patients
T1  - Istraživanje značaja farmaceutske zdravstvene zaštite u unapređenju znanja o inhalacionoj terapiji i njenoj pravilnoj primeni kod pacijenata sa astmom
VL  - 63
IS  - 5
SP  - 419
EP  - 430
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2048
ER  - 

@article{
author = "Antonić, Roland and Jovanović, Marija and Golubović, Bojana and Vučićević, Katarina and Ćulafić, Milica and Miljković, Branislava and Vezmar-Kovačević, Sandra",
year = "2013",
abstract = "Introduction: Insufficient patient knowledge about asthma treatment and inappropriate inhalation techniques contribute to treatment failure. The aim of this study was to investigate the impact of a pharmaceutical care service for asthma patients on improving knowledge about drug purpose and adverse reactions as well as appropriate inhalation technique. Material and methods: Asthma patients with no previous pharmaceutical care (PC) counseling participated in the study, conducted in Pharmacy 'Šabac' during january-april 2010. Data were collected about purpose of drugs, adverse reactions and inhalation technique. During january-april 2013 the investigation was repeated with patients who were offered PC priorly which comprised verbal and written education about purpose of drugs, adverse reactions and inhalation technique. Results: The first group consisted of 128 and the second of 65 patients, with the same average age (56 years). Patients who were offered PC had better knowledge of drug purpose in asthma treatment (91.4-94.0% vs 62.6-75.0%, p lt 0.01) and increased number of adverse reactions (16.0-17.2% vs 3.7-7.5%). Following PC, inhalation technique improved significantly (70.8% vs 38.3% of patients, p lt 0.001) and the average number of mistakes during inhalation decreased (1.33 vs 0.43, p lt 0.001). Conclusion: Asthma patients have insufficient knowledge about their treatment and often use inhalers inappropriately. Pharmacists, by providing PC can contribute significantly to efficient and safe asthma treatment., Uvod: Nedovoljno znanje pacijenata obolelih od astme o savremenoj terapiji i pravilnom načinu njene primene znatno može doprineti neuspehu terapije. Cilj ovog istraživanja bio je ispitivanje doprinosa farmaceutske zdravstvene zaštite (FZZ) edukaciji pacijenata sa astmom, s posebnim osvrtom na pravilnu primenu inhalacione terapije. Materijal i metode: U ispitivanju, sprovedenom u Apoteci 'Šabac' u periodu od januara do aprila 2010. godine, učestvovali su pacijenti sa astmom, kojima prethodno nije pružena FZZ. Prikupljeni su podaci o pacijentima, terapiji koju koriste, neželjenim reakcijama i načinu primene inhalacionih preparata. U periodu od januara do aprila 2013. godine istraživanje je ponovljeno sa pacijentima kojima je prethodno pružena FZZ, koja je obuhvatala pisanu i usmenu edukaciju o nameni lekova, neželjenim reakcijama i pravilnoj tehnici inhalacije. Rezultati: U prvoj grupi je bilo 128, u drugoj 65 pacijenata iste prosečne starosti (56 godina). Pacijenti kojima je pružena FZZ pokazali su bolje znanje o primeni lekova u terapiji astme (91,4-94,0% naspram 62,6-75,0%, p lt 0,01) i povećan je broj neželjenih reakcija (16,0­17,2% naspram 3,7-7,5%). Nakon pružene FZZ, značajno je poboljšana pravilna primena inhalacionih preparata (70,8% naspram 38,3% p lt 0,001) i smanjen je prosečan broj grešaka prilikom inhalacije (1,33 prema 0,43, p lt 0,001). Zaključak: Pacijenti sa astmom nemaju potrebno znanje o inhalacionoj terapiji i često greše u tehnici inhalacije. Farmaceuti, pružanjem usluge FZZ, mogu dati značajan doprinos efikasnoj i bezbednoj terapiji pacijenata sa astmom.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Investigation of the impact of pharmaceutical care on improvement of treatment knowledge and inhalation technique in asthma patients, Istraživanje značaja farmaceutske zdravstvene zaštite u unapređenju znanja o inhalacionoj terapiji i njenoj pravilnoj primeni kod pacijenata sa astmom",
volume = "63",
number = "5",
pages = "419-430",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2048"
}

Antonić, R., Jovanović, M., Golubović, B., Vučićević, K., Ćulafić, M., Miljković, B.,& Vezmar-Kovačević, S.. (2013). Investigation of the impact of pharmaceutical care on improvement of treatment knowledge and inhalation technique in asthma patients. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 63(5), 419-430.
https://hdl.handle.net/21.15107/rcub_farfar_2048

Antonić R, Jovanović M, Golubović B, Vučićević K, Ćulafić M, Miljković B, Vezmar-Kovačević S. Investigation of the impact of pharmaceutical care on improvement of treatment knowledge and inhalation technique in asthma patients. in Arhiv za farmaciju. 2013;63(5):419-430.
https://hdl.handle.net/21.15107/rcub_farfar_2048 .

Antonić, Roland, Jovanović, Marija, Golubović, Bojana, Vučićević, Katarina, Ćulafić, Milica, Miljković, Branislava, Vezmar-Kovačević, Sandra, "Investigation of the impact of pharmaceutical care on improvement of treatment knowledge and inhalation technique in asthma patients" in Arhiv za farmaciju, 63, no. 5 (2013):419-430,
https://hdl.handle.net/21.15107/rcub_farfar_2048 .